Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04336293
Other study ID # D3338-P
Secondary ID RX003338
Status Completed
Phase N/A
First received
Last updated
Start date September 7, 2021
Est. completion date December 29, 2023

Study information

Verified date January 2024
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if synchronized transcranial magnetic stimulation is safe and tolerable in individuals with cocaine, opioid, or alcohol use disorders.


Description:

All non-life-saving human research studies suspended by sponsor in response to COVID19 social distancing policies The goal of this proposal is to evaluate preliminary participant response to a pilot, controlled, feasibility study to evaluate changes in craving, substance use, and quality of life after 6 weeks of a low-risk non-invasive brain stimulation technique, called Synchronized Transcranial Magnetic Stimulation (sTMS), compared to sham, in Veterans with a substance use disorder (SUD). An important focus of this application will be evaluating the acceptability, tolerability, and safety of sTMS in this population. To the investigators knowledge, sTMS has never been used for SUDs, and holds considerable promise as a future treatment option for these prevalent disorders. However initial work in the acceptability, tolerability, and safety of this approach must be conducted first. This project is the first step towards the investigators long-term goal, which is to combine non-invasive brain stimulation with individualized psychotherapy or pharmacotherapy to reduce SUD problems and improve quality of life for Veterans.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date December 29, 2023
Est. primary completion date October 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Eligible male and female Veterans - between ages 18-70, - Veterans who currently meet criteria for SUD, and, if applicable, have stable treatment regimen (i.e., medications and/or therapy) for at least 6 weeks prior to study procedures - ongoing medications and psychotherapy will be allowed to continue unchanged during the study - for safety, participants must also meet established criteria for MRI exposure, which is implemented as a conservative measure given the novel application of sTMS in this population Exclusion Criteria: - pregnancy/lactation, - history of moderate or severe traumatic brain injury, - current or prior neurologic disorder or lifetime history of - seizure disorder - CNS tumors - stroke - cerebral aneurysm, - unstable medical condition, - active suicidality as assessed with the Columbia-Suicide Severity Rating Scale - primary psychotic disorder.

Study Design


Intervention

Device:
sTMS
sTMS will be delivered following NeoSync guidelines using the device user manual
sham sTMS
sham sTMS will be delivered following NeoSync guidelines using the device user manual

Locations

Country Name City State
United States Providence VA Medical Center, Providence, RI Providence Rhode Island

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) Quality of Life Enjoyment and Satisfaction Questionnaire
The Q-LES-Q-SF evaluates general activities that are assessed in the longer form of the Q- LES-Q. Each item uses a 5-point scale ranging from 1 (very poor) to 5 (very good). A total score is derived from 14 items with a maximum score of 70 and with higher scores indicating greater life satisfaction and enjoyment.
6 weeks
Primary substance specific craving self reported reactivity to associated cues with 8 items ranked 1-7--higher scores indicating greater craving/urges 6 weeks
Primary Social and Occupational Functioning Assessment Scale (SOFAS) The SOFAS is a global rating of current functioning ranging from 0 to 100, with lower scores representing lower functioning. 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT01822587 - Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving Phase 2
Completed NCT01601743 - Exercise as a Behavioral Treatment for Cocaine Dependence N/A
Completed NCT02563769 - Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study Phase 1
Completed NCT01651377 - Pramipexole as a Treatment for Cocaine Dependence Phase 1
Completed NCT02768441 - Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots Early Phase 1
Completed NCT02626494 - Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Phase 4
Recruiting NCT02892851 - Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction. N/A
Not yet recruiting NCT01319214 - Reducing Drug Craving Memories N/A
Recruiting NCT01259362 - Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients Phase 2
Completed NCT01211418 - Integrative Meditation (IM) for Cocaine Addiction N/A
Recruiting NCT03423667 - Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction Phase 2
Completed NCT01984177 - Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence N/A
Completed NCT01887366 - Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects Phase 2
Completed NCT01337297 - Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction Phase 1/Phase 2
Completed NCT01067846 - Cognitive Enhancement and Relapse Prevention in Cocaine Addiction N/A
Completed NCT01651364 - A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence Phase 1
Recruiting NCT03018236 - Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Phase 4
Completed NCT01929343 - Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving Phase 2
Completed NCT01281202 - Vigabatrin for the Treatment of Cocaine Dependency Phase 2/Phase 3